Related Experiment Videos
Hemophagocytic reticulosis. A case report with investigations of immune and white cell function
Insights
This study details a 5-month-old with hemophagocytic reticulosis, showing improved lymphocyte response after chemotherapy. Persistent defects in glucose oxidation and IgA levels were noted, but the child remains well on treatment.
Area of Science:
- Pediatric Hematology
- Immunology
- Oncology
Background:
- Hemophagocytic reticulosis (HLH) is a rare, life-threatening hyperinflammatory syndrome.
- Early diagnosis and treatment are crucial for patient survival.
- Understanding the underlying immune dysregulation is key to managing HLH.
Observation:
- A 5-month-old infant presented with clinical signs of hemophagocytic reticulosis.
- Initial investigations revealed a significantly impaired phytohemagglutinin (PHA) response in the patient's lymphocytes.
- Defective glucose oxidation in phagocytic cells and low immunoglobulin A (IgA) levels were also observed.
Findings:
- Chemotherapy led to a notable improvement in the PHA response of lymphocytes.
- Despite treatment, defective glucose oxidation and low IgA levels persisted.
- Human Leukocyte Antigen (HL-A) typing and chromosomal studies ruled out maternal lymphocyte engraftment.
Implications:
- This case highlights the complex immune abnormalities in hemophagocytic reticulosis.
- The partial recovery of lymphocyte function suggests potential therapeutic targets.
- Long-term monitoring for persistent immune defects is warranted in HLH survivors.
Abstract:
A 5-month-old child with hemophagocytic reticulosis is described. Investigations revealed a grossly defective PHA response of the patient's lymphocytes which improved with chemotherapy. Defective glucose oxidation by phagocytosing cells and low IgA levels were demonstrated at diagnosis and have persisted despite chemotherapy. HL-A typing and chromosome studies did not reveal maternal lymphocytes in the child's circulation. The patient was treated with vinblastine and prednisolone and remains well after 11 months of treatment.